普拉洛芬联合埃美丁治疗过敏性结膜炎的有效性与安全性分析

杜微; 马莹颖; 付乐铭; 李俊

doi:10.16766/j.cnki.issn.1674-4152.003798

普拉洛芬联合埃美丁治疗过敏性结膜炎的有效性与安全性分析

doi: 10.16766/j.cnki.issn.1674-4152.003798

杜微^1, ,,
马莹颖¹,
付乐铭¹,
李俊²

1.
绍兴市妇幼保健院眼科，浙江绍兴 312000
2.
丽水市中心医院眼科，浙江丽水 323020

基金项目:

浙江省医药卫生科技计划项目 2020RC151

详细信息

通讯作者:
杜微，E-mail：13867512525@163.com

中图分类号: R777.31
计量
- 文章访问数: 8
- HTML全文浏览量: 9
- PDF下载量: 3
- 被引次数: 0
出版历程
- 收稿日期: 2024-08-22
- 网络出版日期: 2025-01-20

Analysis of the efficacy and safety of Pralofen combined with Emadine in the treatment of allergic conjunctivitis

DU Wei^{1
, ,},
MA Yingying¹,
FU Leming¹,
LI Jun²

1.
Department of Ophthalmology, Shaoxing Maternal and Child Health Hospital, Shaoxing, Zhejiang 312000, China

摘要

摘要: 目的过敏性结膜炎(AC)是一种常见的眼表疾病，单一药物治疗虽能缓解症状，但疗效有限且复发率高，因此探索联合用药策略以优化治疗方案具有重要意义。本研究旨在探讨普拉洛芬联合埃美丁治疗AC的有效性与安全性，为临床制定治疗方案提供借鉴。方法选取2023年10月—2024年6月绍兴市妇幼保健院眼科收治的124例AC患者，采用随机数表法分为A组(62例)与B组(62例)，A组予以普拉洛芬治疗，B组予以普拉洛芬联合埃美丁治疗。观察2组患者的症状改善情况、泪膜稳定性、泪液指标水平、炎性因子水平、临床疗效及不良反应发生情况。结果 B组患者治疗后的畏光、流泪、眼痒、眼分泌物评分均低于A组(P＜0.05)。B组治疗后的泪膜破裂时间(BUT)长于A组、角膜荧光素染色试验(CFS)评分低于A组(P＜0.05)。B组治疗后的嗜酸性细胞阳离子蛋白(ECP)、组胺(HA)、白三烯B4(LTB4)均低于A组(P＜0.05)。B组治疗后的IL-6、TNF-α、hs-CRP均低于A组(P＜0.05)。B组的总有效率为91.94%(57/62)，高于A组的75.81%(47/62)，差异有统计学意义(P＜0.05)。B组的不良反应发生率为8.06%(5/62)，略低于A组的12.90%(8/62)，但差异无统计学意义(P＞0.05)。结论普拉洛芬联合埃美丁治疗AC的效果较好，可有效减轻患者症状，提高泪膜稳定性，改善泪液指标水平与炎性因子水平，且不良反应少，有效性与安全性兼具，值得推行。
- 过敏性结膜炎 /
- 普拉洛芬 /
- 埃美丁 /
- 有效性 /
- 安全性
Abstract: Objective Allergic conjunctivitis (AC) is a common ocular surface disease. Although single-drug treatment can alleviate symptoms, the efficacy is limited, and the recurrence rate is high. Therefore, exploring combination therapy strategies to optimize treatment plans is of great significance. The aim of this study is to investigate the efficacy and safety of Pralofen combined with Emadine in the treatment of AC, providing, reference for clinical treatment planning. Methods A total of 124 patients with AC admitted to the ophthalmology department of our hospital from October 2023 to June 2024 were randomly divided into Group A and Group B. Group A, consisting of 62 patients, was treated with Pralofen, while Group B, consisting of 62 patients, was treated with Pralofen combined with Emadine. The improvement of symptoms, tear film stability, tear index levels, inflammatory factor levels, clinical efficacy, and adverse reactions were observed in both groups. Results The scores of photophobia, tearing, eye itching, and eye secretions in group B were lower than those in group A after treatment (P < 0.05). The BUT of group B after treatment was longer than that of group A (P < 0.05), and the CFS score was lower than that of group A (P < 0.05). The ECP, HA, and LTB4 levels in group B were lower than those in group A after treatment (P < 0.05). The levels of IL-6, TNF-α, and hs-CRP in group B were lower than those in group A after treatment (P < 0.05). The total effective rate of Group B was 91.94% (57/62), which was higher than that of Group A [75.81% (47/62)], with P < 0.05. The incidence of adverse reactions in Group B was 8.06% (5/62), which was slightly lower than that of Group A [12.90% (8/62)], with P>0.05. Conclusion Pralofen combined with Emadine has a good effect on the treatment of AC, which can effectively alleviate patient symptoms, improve tear film stability, improve tear index levels and inflammatory factor levels, and has fewer adverse reactions. It is effective and safe and is worth promoting.
- Allergic conjunctivitis /
- Pralofen /
- Emadine /
- Effectiveness /
- Security

HTML全文

表 1 2组过敏性结膜炎患者症状改善情况比较(x±s，分)

Table 1. Comparison of symptom improvement between the two groups of allergic conjunctivitis patients (x±s, points)

组别	例数	畏光		流泪		眼痒		眼分泌物
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
A组	62	2.26±0.55	1.15±0.27^b	2.40±0.47	1.06±0.32^b	2.20±0.51	1.01±0.25^b	2.14±0.34	0.92±0.21^b
B组	62	2.29±0.53	0.83±0.22^b	2.43±0.45	0.78±0.20^b	2.22±0.48	0.78±0.21^b	2.17±0.31	0.64±0.14^b
统计量		0.309^a	6.326^c	0.363^a	5.157^c	0.225^a	5.024^c	0.513^a	7.925^c
P值		0.758	＜0.001	0.717	＜0.001	0.823	＜0.001	0.608	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 2 2组过敏性结膜炎患者泪膜稳定性比较(x±s)

Table 2. Comparison of tear film stability between the two groups of allergic conjunctivitis patients (x±s)

组别	例数	BUT(s)		CFS评分(分)
组别	例数	治疗前	治疗后	治疗前	治疗后
A组	62	8.12±1.26	10.84±1.35^b	8.35±1.02	2.93±0.31^b
B组	62	8.08±1.29	13.32±1.47^b	8.39±1.00	1.84±0.22^b
统计量		0.175^a	8.783^c	0.220^a	20.425^c
P值		0.862	＜0.001	0.826	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 3 2组过敏性结膜炎患者泪液指标水平比较(x±s)

Table 3. Comparison of tear index levels between the two groups of allergic conjunctivitis patients (x±s)

组别	例数	ECP(μg/L)		HA(μg/L)		LTB4(pg/mL)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
A组	62	12.35±3.13	6.73±1.84^b	205.62±35.13	62.42±10.34^b	113.35±12.63	87.34±7.26^b
B组	62	12.39±3.10	3.64±1.12^b	208.12±34.92	36.73±7.20^b	113.63±12.57	75.73±6.31^b
统计量		0.071^a	10.142^c	0.397^a	14.838^c	0.124^a	8.136^c
P值		0.943	＜0.001	0.692	＜0.001	0.902	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

表 4 2组过敏性结膜炎患者炎性因子水平比较(x±s)

Table 4. Comparison of inflammatory factor levels between the two groups of allergic conjunctivitis patients (x±s)

组别	例数	IL-6(pg/mL)		TNF-α(ng/mL)		hs-CRP(mg/L)
组别	例数	治疗前	治疗后	治疗前	治疗后	治疗前	治疗后
A组	62	162.89±22.42	100.43±16.65^b	3.76±0.42	2.42±0.27^b	13.52±2.78	9.83±1.86^b
B组	62	163.11±22.25	67.29±12.63^b	3.79±0.40	1.70±0.21^b	13.59±2.73	7.79±1.32^b
统计量		0.055^a	11.106^c	0.407^a	14.047^c	0.141^a	5.944^c
P值		0.956	＜0.001	0.684	＜0.001	0.888	＜0.001
注：^a为t值，^c为F值；与同组治疗前比较，^bP＜0.05。

下载: 导出CSV

参考文献(22)

[1]	LEONARDI A, QUINTIERI L, PRESA I J, et al. Allergic conjunctivitis management: update on ophthalmic solutions[J]. Curr Allergy Asthma Rep, 2024, 24(7): 347-360. doi: 10.1007/s11882-024-01150-0
[2]	LIU K C, CAI Y J, SONG K, et al. Clarifying the effect of gut microbiota on allergic conjunctivitis risk is instrumental for predictive, preventive, and personalized medicine: a Mendelian randomization analysis[J]. EPMA J, 2023, 14(2): 235-248. doi: 10.1007/s13167-023-00321-9
[3]	李晓庄, 殷文静, 范其佩, 等. 奥洛他定联合普拉洛芬治疗过敏性结膜炎疗效和安全性的meta分析[J]. 国际眼科杂志, 2022, 22(11): 1844-1850. LI X Z, YIN W J, FAN Q P, et al. Meta analysis of the efficacy and safety of Olopathidine combined with Pralofen in the treatment of allergic conjunctivitis[J]. International Journal of Ophthalmology, 2022, 22(11): 1844-1850.
[4]	李昆, 李鹏, 刘擎. 富马酸依美斯汀联合氟米龙滴眼液治疗过敏性结膜炎[J]. 国际眼科杂志, 2024, 24(6): 1000-1004. LI K, LI P, LIU Q. Treatment of allergic conjunctivitis with Emestine fumarate combined with Flumerone eye drops[J]. International Journal of Ophthalmology, 2024, 24(6): 1000-1004.
[5]	中华医学会眼科学分会角膜病学组. 我国过敏性结膜炎诊断和治疗专家共识(2018年)[J]. 中华眼科杂志, 2018, 54(6): 409-414. Corneal Disease Group of the Ophthalmology Branch of the Chinese Medical Association. Expert consensus on diagnosis and treatment of allergic conjunctivitis in China (2018)[J]. Chinese Journal of Ophthalmology, 2018, 54(6): 409-414.
[6]	黄海东, 袁志敏, 邢杰, 等. 色甘酸钠联合双氯芬酸钠滴眼液治疗过敏性结膜炎的疗效[J]. 中国医师杂志, 2022, 24(8): 1215-1219. HUANG H D, YUAN Z M, XING J, et al. Efficacy of sodium Selenate combined with Diclofenac sodium eye drops in the treatment of allergic conjunctivitis[J]. Chinese Journal of Physicians, 2022, 24(8): 1215-1219.
[7]	徐艳, 林智, 吴育芝. 奥洛他定滴眼液联合普拉洛芬滴眼液治疗过敏性结膜炎患者的临床研究[J]. 中国临床药理学杂志, 2023, 39(3): 345-348. XU Y, LIN Z, WU Y Z. Clinical study on the treatment of allergic conjunctivitis patients with Olotadine eye drops combined with Pralofen eye drops[J]. Chinese Journal of Clinical Pharmacology, 2023, 39(3): 345-348.
[8]	许行艳, 潘可生. 曲安奈德联合氟米龙滴眼液治疗过敏性结膜炎的临床研究[J]. 现代药物与临床, 2023, 38(7): 1742-1745. XU X Y, PAN K S. Clinical study on the treatment of allergic conjunctivitis with Triamcinolone acetonide combined with Flumeron eye drops[J]. Modern Medicine and Clinical, 2023, 38(7): 1742-1745.
[9]	KALANGARA J P, VANIJCHAROENKARN K, CHISOLM S, et al. Neuropathic pain and itch: mechanisms in allergic conjunctivitis[J]. Curr Opin Allergy Clin Immunol, 2022, 22(5): 298-303.
[10]	CRETICOS P S, GUNAYDIN F E, NOLTE H, et al. Allergen immunotherapy: the evidence supporting the efficacy and safety of subcutaneous immunotherapy and sublingual forms of immunotherapy for allergic rhinitis/conjunctivitis and asthma[J]. J Allergy Clin Immunol Pract, 2024, 12(6): 1415-1427.
[11]	DOGAN C U, TUZER C, TURKER I C, et al. Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis[J]. Int Ophthalmol, 2023, 43(7): 2161-2169.
[12]	MONTERO-IRUZUBIETA J, SANCHEZ HERNANDEZ M C, DAVILA I, et al. The importance of preventing and managing tear dysfunction syndrome in allergic conjunctivitis and how to tackle this problem[J]. J Investig Allergol Clin Immunol, 2023, 33(6): 439-445.
[13]	SALONEN J, REMITZ A, SALONEN J, et al. Allergic conjunctivitis: a risk factor for recurrent herpes simplex virus infections in patients with atopic dermatitis[J]. Eur J Dermatol, 2022, 32(5): 607-614.
[14]	TANAKA H, TATSUKAWA Y, YOSHITOMI K, et al. Effects of antihistamine-releasing contact lenses on severe allergic conjunctivitis[J]. Ocul Immunol Inflamm, 2023, 31(8): 1674-1676.
[15]	GENG Z, GAO L, LI C Y, et al. The necessity of pretreatment with 0.1% pranoprofen for femtosecond-assisted cataract surgery: a single-center, randomized controlled trial[J]. Adv Ophthalmol Pract Res, 2023, 20(4): 153-158.
[16]	LU H W, GUAN Y Q, SU Y D, et al. Effect of sodium hyaluronate eye drops combined with tobramycin, dexamethasone and pranoprofen eye drops in the treatment of dry eye after phacoemulsification[J]. Indian J Ophthalmol, 2022, 70(12): 4319-4324.
[17]	CHEN T, ROELOFS K A, ROOTMAN D B. Allergic conjunctivitis and contact dermatitis following silicone tube intubation[J]. Can J Ophthalmol, 2023, 58(1): 36-38.
[18]	DOU X Y, ZHANG W. Topical ketotifen treatment for allergic conjunctivitis: a systematic review and meta-analysis[J]. Int J Ophthalmol, 2023, 16(2): 286-292.
[19]	LI S Y, ZHONG S Q. Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study[J]. Postepy Dermatol Alergol, 2023, 40(2): 326-330.
[20]	TAJBAKHSH Z, GOLEBIOWSKI B, STAPLETON F, et al. Increased dendritic cell density and altered morphology in allergic conjunctivitis[J]. Eye (Lond), 2023, 37(14): 2896-2904.
[21]	畅立斌, 蔡小会. 色素失禁症相关性视网膜病变眼前房水多因子分析[J]. 中国临床医生杂志, 2021, 49(11): 1375-1378. CHANG L B, CAI X H. Multifactor analysis of anterior aqueous humor in retinal lesions associated with pigment incontinence[J]. Chinese Journal of Clinical Physicians, 2021, 49(11): 1375-1378.
[22]	郝泽林, 吴建跃, 滕振飞, 等. 急性脑梗死患者血清学指标与神经功能缺损和脑梗死体积及颈动脉斑块性质的相关性研究[J]. 中华全科医学, 2020, 18(11): 1803-1806. doi: 10.16766/j.cnki.issn.1674-4152.001623 HAO Z L, WU J Y, TENG Z F, et al. Study on the correlation between serological indicators and neurological deficits, cerebral infarction volume, and carotid plaque properties in patients with acute cerebral infarction[J]. Chinese Journal of General Practice, 2020, 18(11): 1803-1806. doi: 10.16766/j.cnki.issn.1674-4152.001623